Nuvectis Pharma Investor Presentation Deck
Targeting YES1 in Cancers of Squamous Cell Origin
Single agent development strategy
YES1/SRC
"off"
SH3
SH2
PYS30
NOP900
1419
Kinase
V530
SH2
E
YES1/SRC
"on"
P
PY419
Kinase
Created with BioRender.com
NuvectisPharma, Inc.
P-
Tyr
Rassf
YAP/TAZ
P.
Tyr YAP/TAZ
TEAD
хото
P
P
FRMD6
KIBRA
MST1/2 SAV1
LATS1/2 MOB1
FAT
1-4
14-3-3
P
YAP/TAZ
Merlin
P
P-
Ser
(50)
Targets involved in organ size,
stem cell renewal, replication,
and survival:
• ID1
• MYC
abox. FGF1
Degradation
• CTGF • Cyclin D
. AREG
• SMAD
High Nuclear YAP Cells Per Well (%)
Low Nuclear
YAP
-5.0
High Nuclear
YAP
NXP900 - IC50 for YAP1
nuclear localization: 24.3nM
I
log(Concentration [UM])
0.0
25
Genetic alterations in the hippo
pathway (FAT1-4, YAP1, TAZ) are
highly prevalent in cancers of
squamous cell origin and confer
sensitivity to NXP900 ➜ patient
selection
YES1 drives tumor growth via
activating phosphorylation and nuclear
localization of YAP1 →Target is
central to disease etiology
Significant unmet medical need
opportunities within the squamous
cancer universe Regulatory
opportunity
18View entire presentation